Document is current

Article History

Received: 29 October 2025

Accepted: 8 February 2026

First Online: 31 March 2026

Declarations

:

: Not applicable.

: Not applicable.

: The National Diagnostic and Care Protocol (PNDS) for MODY was developed by accredited reference and competence PRISIS centers, with methodological support from the French National Health Authority (HAS), in application of the provisions of the National Rare Diseases Plan 2005–2023. This new version is placed under the sole editorial responsibility of the PRISIS network.

: The authors declare that they have no competing interests related to the content of the present manuscript. BD reports past consulting fees/meeting fees from Sanofi and speaking fees from Novartis, Lilly, Sanofi. CVa reports consulting fees/meeting fees from Chiesi, Lilly, MSD, Menarini, NovoNordisk, Sanofi, Aegerion, AstraZeneca, Abbott, Advanz pharma, Amryt, Rhythm, and research funding from Sanofi. CVi reports lecture fees from Amryt Pharmaceuticals (now Chiesi Farmaceutici), Sanofi and Gilead. EB reports consulting fees/meeting fees from Medtronic, Abbot, Lilly, Insulet, speaking fees from NovoNordisk, Lilly, Orkyn, Abbot, DinnoSanté and research funding from Lilly. IT reports consulting fees/meeting fees from MSD, Pfizer SAS, Pharma Dom, Novartis, Astra Zeneca, Sanofi, Recordati Rare Disease. JCN reveiced research grants from Bayer and Ipsen. MCV served as investigator in the APL-22 clinical study sponsored by Chiesi Farmaceutici. PB reports consulting fees/meeting fees from Abbott, Lilly, NovoNordisk, Dexcom, Sanofi. PG reports consulting fees/meeting fees from Abbott, Abbvie, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Pfizer, and Sanofi.